Outlook 2024
Annual Industry Ranking And Forecast
VIEW NOWScrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
Vertex and bluebird compete for sickle cell patients, BioMarin talks about divesting Roctavian, and Sarepta warned that sales of Elevidys will plateau with a narrow label.
The drug maker has its eye on six Phase III or Phase III-ready programs that it hopes will return the company to growth. It also highlighted investments in AI and digital technology.
Combination mechanisms, less frequent dosing and scalability are the goals of the collaboration.
A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Recent moves in the industry include new CEOs at Juno Pharmaceuticals and YS Biopharma, plus Glenmark gets a new chief communications officer.
Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on those large components of pharma, Sanofi’s reclassification may bring some unwelcome attention.
Aiming to help create China’s first original treatment for under-researched rare diseases, the Hope for Rare Foundation is racing against a funding crunch to support translational research in China, its co-founder and secretary-general tells Scrip in an interview.
Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.
The attraction of listing in the US for innovative companies is clear but the heads of the Swiss Biotech Association tell Scrip that start-ups should remember the advantages of playing at home and not waste too much energy and time on worrying about being on the NASDAQ.
In this video interview, Sharon Chan, vice-president, Johnson & Johnson Innovation – JLABS Asia Pacific, shares her views on what South Korea’s strengths are as a biotech and medtech R&D hub, JLABS's plans in the country and what role it wants for its local activities domestically and beyond.
Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
The US biotech’s DB-OTO has made headlines worldwide after a baby with profound genetic deafness experienced improved hearing to normal levels within 24 weeks after a single intracochlear injection.
Recent moves in the industry include new CEOs at Juno Pharmaceuticals and YS Biopharma, plus Glenmark gets a new chief communications officer.
Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.
As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston.
Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.
Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.
Early-stage companies pioneering new modalities discussed the future of cardiometabolic therapy and partnering with big pharma at the LSX conference in London.
The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.
Aiming to help create China’s first original treatment for under-researched rare diseases, the Hope for Rare Foundation is racing against a funding crunch to support translational research in China, its co-founder and secretary-general tells Scrip in an interview.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.